Office of Research Oversight 1 VHA Handbook 1058.01 Research Compliance Reporting Requirements HRPP 101 - September 30 2010.

Slides:



Advertisements
Similar presentations
The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
Advertisements

Office of Research Oversight Reporting: Who, What, When, and Why February, 2012.
Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB
Gerald Treiman, IRB Chair John Stillman, IRB Director Maureen Brinkman, IRB Administrator Ann Johnson, IRB Administrator.
Safety Reporting IN Clinical Trials
UNANTICIPATED PROBLEMS INVOLVING RISKS TO SUBJECTS OR OTHERS & INCIDENTS OF NON-COMPLIANCE ( AKA PROTOCOL DEVIATIONS ) TRACY RIGHTMER, JD, CIP COMPLIANCE.
SOP Melody Lin, Ph.D. Deputy Director, Office for Human Research Protections Director, International Activities Santiago, Chile August.
Reporting Unanticipated Problems Involving Risk to Subjects or Others and Adverse Events WFUHS Policy/Procedure Effective Date 6/1/07 Wendy Murray Monitoring.
Office of Research Oversight. Challenges & Opportunities Related to “Collaborative” Research with Affiliates Challenges –Federal Records Retention Requirements.
IRB Determinations 1. AAHRPP Site Visit Results Site visitors observed a real commitment to human subject protections Investigator and research staff.
1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.
Human Subjects Protection: Creation and Maintenance of an IRB Regulatory Requirements & Recommendations 45 CFR part 46 Freda E. Yoder Office for Human.
Update: 21 CFR PART 312 FDA Safety Reporting Requirements for INDs
Capturing and Reporting Adverse Events in Clinical Research
Pharmacists Responsibilities in Clinical Studies Mike R Sather, PhD Crystal L Harris, PharmD February 26, 2004.
IRB-Investigator/ Research Coordinator Mtg. “CUMC’s New Progressive Policy For Adverse Event Reporting” April 13, 2004 George Gasparis Andrew Wit, Ph.D.
CUMC IRB Investigator Meeting Human Subjects Research Non-Compliance September 15, 2005.
Human Research Protection Program Training: Post-Approval Event Reporting March 26, 2008 Lisa Voss, MPH, CIP Assistant Director, QIU Human Research Protection.
Office of Research Oversight VHA Handbook Research Conducted by VHA Program Office Employees Effective May 1, 2012 October 28, 2011.
HRPP Policies & Forms Created/Revised for AAHRPP.
Office of Research Oversight Update VA IRB Chair Meeting Baltimore, Maryland August 14-15, 2012 August 14, 2012.
Reality vs Urban Myth: The Truth About Regulations
Defining Unanticipated Problems Involving Risks to Subjects or Others (UPIRSO)
Continuing Review VA Requirements Kevin L. Nellis, M.S., M.T. (A.S.C.P.) Program Analyst Program for Research Integrity Development and Education (PRIDE)
Federalwide Assurance Presentation for IRB Members.
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.
Responsible Conduct of Research (RCR) Farida Lada October 16, 2013
ORO Reviews: Frequent Findings Related to IRBs Bob Brooks Associate Director Research Compliance Education and Policy VHA Office of Research Oversight.
Reporting Unanticipated Problems and Adverse Events: A Change in Policy Mary A. Banks RN, BS, BSN Director, BUMC IRB Wednesday, November 14, 2007.
Unanticipated Problems Potentially Involving Risks to Subjects or Others Research Protections Office Serving UVM and FAHC Updated April 2012.
New Adverse Event Reporting Policy Effective September 1, 2007.
Office of Research Oversight ORO Reporting Adverse Events in Research to ORO Paula Squire Waterman, MS, CIP Department of Veterans Affairs Office of Research.
Sara Brand Associate Director Research Compliance Administration.
Michelle Groy Johnson Quality Improvement Officer Research Integrity Office Tough Love: Understanding the Purpose and Processes of Quality Assurance.
Adverse Event/Unanticipated Problems Policy and Procedures November 2007.
Research Auditing Presented by: Darlene Krueger, MBA RN CCRA Chief, GCP Auditing & Training VA Cooperative Studies Program Albuquerque, NM.
ORO Reviews: Frequent Findings Bob Brooks Associate Director Research Compliance Education and Policy VHA Office of Research Oversight May, 2012.
Office of Research Oversight 1 VHA Handbook Research Compliance Reporting Requirements Revised May 21, 2010 (Presentation prepared for HRPP 101,
JERI R. BARNEY, JD HRPP COMPLIANCE MANAGER YALE UNIVERSITY HUMAN RESEARCH PROTECTION PROGRAM DECEMBER 13, 2012 Noncompliance.
Privacy and Confidentiality. Definitions n Privacy - having control over the extent, timing, and circumstances of sharing oneself (physically, behaviorally,
VHA Handbook “Research Compliance Reporting Requirements” Version: June 15, 2015 ORO Presentation: July 14 and 16, 2015.
Office of Research & Development (ORD) Local Accountability of Research 2009 Baltimore, Maryland January 13-14, 2009 “Meeting the Current Challenges of.
Human Research Protection Program & IRB Responsibilities Marisue Cody, PhD Director Center on Advice & Compliance Help.
AUDIT REQUIREMENTS, FINDINGS & BASICS RESEARCH COMPLIANCE.
Office of Research Oversight 1 ORO Research Suspensions and Other ACOS/R Concerns Tom Puglisi, PhD Local Accountability in Research April 8, 2010.
OBSERVED IN ORO REVIEWS COMPLIANCE ISSUES: OBSERVED IN ORO REVIEWS David A. Weber, Ph.D., FACNP Acting Chief Officer Office of Research.
Continuing Review Presented by: Karen Jeans, PhD, CCRN, CIP Program Analyst, COACH.
VHA Research Compliance Reporting Requirements ORD Accreditation Conference Call December 15, 2011.
Investigational Devices and Humanitarian Use Devices June 2007.
Office of Research Oversight 1 Core Responsibilities for Human Research Protection Research Compliance Officers Robert Brooks, MD, PhD, MBA Associate Director,
Case Studies: Puzzles in Human Research Kevin L. Nellis, M.S., M.T. (A.S.C.P.) Program Analyst, Program for Research Integrity Development and Education.
The NCI Central IRB Initiative Jacquelyn L. Goldberg, J.D. VA IRB Chair Training April 8, 2004.
HRPP Policies & Forms Chapter Two Created/Revised for AAHRPP June 1, 2007.
Office of Research Oversight 1 Office of Research and Development Local Accountability Meeting January 2009.
The TJU Human Research Protection Program (HRPP) Part II, Conflict of Interest and IRB Noncompliance J. Bruce Smith, MD, CIP.
Office of Research & Development (ORD) Local Accountability of Research 2009 Baltimore, Maryland January 13-14, 2009 “Meeting the Current Challenges of.
Office of Research Oversight What’s New in VHA Handbook Dated November 15, 2011 December 1, 2011.
GEORGIA STATE UNIVERSITY IRB ADAPTED FROM DHHS GUIDANCE ON UNANTICIPATED PROBLEMS Unanticipated Problems.
IRB Minutes Karen Jeans, MSN, CCRN, CIP COACH Program Analyst.
Main Line Hospitals Institutional Review Board Unanticipated Problems Anne Marie Hobson, BSN, JD, ORA Director Theresa Greaves, ORA Manager.
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Dartmouth Human Research Protection Program (HRPP) Data Safety Monitoring and Reporting requirements Brown Bag Series: Noon / First Tuesday of the Month.
IRB reporting updates.
Reportable Events & Other IRB Updates February 2017
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Navigating Non-Compliance
SERIOUS ADVERSE EVENTS REPORTING
Policy on Prompt Reporting
Presentation transcript:

Office of Research Oversight 1 VHA Handbook Research Compliance Reporting Requirements HRPP September

Office of Research Oversight 2 Highlights (New Requirements in Red – Previous Requirements in Blue) Requirements for Designation of Facility RCO [ §6c] Requirements to Conduct Annual and Triennial Audits as Specified by ORO [ §6c] Facility Director Reporting Requirements [ §6f] Annual Facility Director Certification of Research Oversight [ §6g] RCO Roles as Consultant to Review Committees [ §4t] Requires Reporting of All RCO Audit Findings to Relevant Review Committees and R&DC [ §§6d, 6e] Time Periods for Implementing Remedial Actions [ §5d] Requires Providing ORO Compliance Reports to ACOS/R, RCO, Relevant Review Committees and R&DC [ §6g]

Office of Research Oversight 3 Highlights (New Requirements in Red – Codification of Previous Guidance in Blue) Distinguishes Rapid Reporting Requirements for Serious Adverse Events and Unanticipated Problems Involving Risks to Subjects or Others from Reporting Requirements Under Local SOPs Clarifies Definitions of Serious or Continuing Noncompliance [ §§4e, 4x] Limits Special Rapid Reporting Requirements for Serious or Continuing Noncompliance to Human Research [ §§4e, 4x] Distinguishes Apparent Serious or Continuing Noncompliance from IRB-Determined Serious/Continuing Noncompliance and Provides Specific Examples[ §7i] Defines “Reportable Events” for Non-Human of Research [ §§8-11]

Office of Research Oversight 4 Role of the RCO RCO’s primary responsibility = auditing and reviewing research projects relative to VA research requirements RCO may also serve as a nonvoting consultant, as needed, to the facility’s R&D Committee, IRB, IACUC, Subcommittee on Research Safety (SRS), and other research review committees The RCO may not serve as a voting or nonvoting member of these committees -- may attend meetings of these committees when requested by the committee or as specified in local committee SOPs [ §4t]

Office of Research Oversight 5 Non-Voting Consultant vs Non-Voting Member Real or Apparent Conflict of Interest RCO audits entail review of IRB actions – the RCO’s perceived independence is compromised if the RCO is a member of the committee under review Flexibility of RCO time and resource commitments Multiple mandatory committee memberships decrease optimal use of RCO time and resources Flexibility in developing working relationship that meet facility research protection and oversight needs [ §4t]

Office of Research Oversight 6 The IRB is responsible for determining: Whether or not apparent noncompliance is serious or continuing Remedial action(s) in response to identified noncompliance Verifying that the remediation is implemented as required. [ §7i]

Office of Research Oversight 7 Remedial Actions Remedial actions related to specific research projects should typically be completed within days of the research review committee’s determination of noncompliance. Except where remediation requires substantial renovation, fiscal expenditure, hiring, legal negotiations, or other extenuating circumstances, remedial actions related to programmatic noncompliance should typically be completed within days of the noncompliance determination. Where completion of remedial actions extends beyond the periods described in the preceding subparagraphs, the facility must provide ORO with a written justification for the delay and an acceptable timeline for completion. [ §5d]

Office of Research Oversight 8 Serious or Continuing Noncompliance vs Apparent Serious or Continuing Noncompliance Serious Noncompliance: Involves substantive harm (or genuine risk of substantive harm) to the safety, rights, welfare of human subjects, research staff or others in human research Substantively compromises the effectiveness of the facility’s human research protection/oversight programs Continuing Noncompliance: Reflects a persistent failure to adhere to the laws, regulations, or policies governing VA human research [ §§4e,4x,7e, 7f, 7g]

Office of Research Oversight 9 Serious or Continuing Noncompliance vs Apparent Serious or Continuing Noncompliance Apparent Serious or Continuing Noncompliance = a situation that, in the judgment of the individual observing it: Satisfies the Handbook’s definition of Serious Noncompliance Satisfies the Handbook’s definition of Continuing Noncompliance Reflects one or more of the examples provided in the Handbook [ §§4e,4x,7e, 7f, 7g]

Office of Research Oversight 10 Apparent Serious or Continuing Noncompliance Observed by an RCO in an Informed Consent, Regulatory, or Other Systematic Audit of Human Subjects Research Must be reported to the Facility Director, IRB, ACOS/R, R&D Committee, etc. within 5 business days Facility Director must report to ORO Regional Office within 5 business days of being notified (even if disposition complete) Facility Director must provide follow-up reports as specified by ORO Regional Office Convened IRB determines whether: Serious or Continuing Noncompliance occurred Remedial Actions are warranted [ §7h]

Office of Research Oversight 11 Apparent Serious or Continuing Noncompliance in Human Subject Research Observed by anyone in the Research Community (including RCO in context other than audit) Must be reported to the IRB within 5 business days Convened IRB determines whether: Serious or Continuing Noncompliance occurred Remedial Actions are warranted If Serious of Continuing Noncompliance, IRB must report to Facility Director, ACOS/R, R&D Committee, etc, within 5 business days Facility Director must report to ORO Regional Office within 5 business days of being notified [ §7i]

Office of Research Oversight 12 Note Change in Reporting Requirements Involving  UNANTICIPATED Adverse Events  UNANTICIPATED Problems Involving Risks to Subjects/Others The 5-day requirement for reporting Adverse Events (AEs) and Problems Involving Risks to Subjects or Others TO THE IRB Now applies only to AEs and Problems that are UNANTICIPATED and SERIOUS

Office of Research Oversight 13 “UNANTICIPATED” refers to an event/problem that is new or greater than previously known in terms of nature, severity, or frequency, given the procedures described in protocol-related documents and the characteristics of the study population. “SERIOUS” refers to: Events that qualify as Serious Adverse Events (SAEs) as defined by FDA; or Problems/events that involve: Substantive harm, or a genuine risk of substantive harm to the safety, rights, or welfare of research subjects, staff, or others; or Substantively compromise the effectiveness of the facility’s human research protection or human research oversight programs

Office of Research Oversight 14 This change is meant to improve oversight by: Decreasing the overload experienced by IRBs from rapidly reviewing large numbers of clinical events that are unlikely to reflect substantive, unconsidered risks Allowing timely expert peer review focused on events that are more likely to reflect substantive concerns All SAEs and Problems Involving Risks to Subjects or Others still require review by the IRB as described in local Standard Operating Procedures consistent with: VHA Handbook , The Common Rule at 28 CFR 16, and Applicable FDA regulations

Office of Research Oversight 15 Serious Adverse Event (SAE) Reporting Investigator (or other person) must report any local AE that is SERIOUS and UNANTICIPATED to the IRB within 5 business days: Serious = untoward physical or psychological occurrence in a human subject resulting in death, life-threatening experience, impatient hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect, or that requires medical, surgical, behavioral, social, or other intervention to prevent such an outcome Unanticipated = reflects a risk that is new or greater than previously known Special review by IRB (or qualified IRB member) within 5 business day after the report to categorize the event [ §§ 4b,4p,4x,4y,4bb,7c, 7d]

Office of Research Oversight 16 Serious Adverse Event (SAE) Reporting IRB must report any Unanticipated, Related, Local SAE to the Facility Director within 5 business days of categorization Related = event may reasonably be regarded as caused by, or as probably caused by, the research Facility Director must report to ORO Regional Office within 5 business days of being notified IRB (or qualified IRB member) must also document whether or not action is needed to prevent immediate hazard to subjects If consent or protocol modifications are required, convened IRB must determine whether previously enrolled subjects must be notified, and if so when, how, and how documented [ §§ 4b,4p,4x,4y,4bb,7c,7d]

Office of Research Oversight 17 Unanticipated Problem Reporting Investigator (or other person) must report any Unanticipated Problem Involving Risks to Subjects or Others in human research to the IRB within 5 business days if it: May reasonably be regarded to involve substantive harm, or a genuine risk of substantive, to safety, rights, or welfare, or Substantively compromises the effectiveness of the facility’s human research protection or human research oversight programs Special review by IRB (or qualified IRB member) required within 5 business days after the report to categorize the event Investigator (or other person) must report any other unanticipated problems involving risks to subjects or others in human research to the IRB promptly per local SOPs [ §§ 4y,4bb,7a,7b,7d]

Office of Research Oversight 18 Unanticipated Problem Reporting IRB must report Related, Serious, Unanticipated Problem Involving Risk to Subjects or Others to Facility Director within 5 business days of categorization Related = event may reasonably regarded as caused by, or as probably caused by, the research Facility Director must report to ORO Regional Office within 5 business days of being notified IRB (or qualified IRB member) must also document whether or not action is needed to prevent immediate hazard to subjects If consent or protocol modifications are required, convened IRB must determine whether previously enrolled subjects must be notified, and if so when, how, and how documented [ §§ 4b,4p,4x,4y,4bb,7c,7d]

Office of Research Oversight 19 Animal Research, Research Safety, Research Lab Security, Research Information Protection, Research Misconduct Reporting not based on “Serious or Continuing Noncompliance” as defined in human research Reportable Events defined for each type of research No special requirements for Rapid Review / Rapid Reporting to ORO 5-day standard for reporting: Reportable Event to Research Review Committee Review Committee Determination to Facility Director To ORO by Facility Director [ §§ 8, 9, 10, 11, 12]

Office of Research Oversight 20 Reportable Events for Animal Research Unanticipated Loss of Animal Life Animal theft or potentially dangerous escape Work-related / research-related injury requiring more than minor medical intervention, extended surveillance, or leading to serious complications or death Reportable incidents under applicable federal standards (examples provided) Noncompliance or deficiency that substantively compromises research animal protection of oversight programs Suspensions or terminations of research related to animal or human welfare; interruptions related to operational problems [ § 8]

Office of Research Oversight 21 Reportable Events for Research Safety Work-related / research-related injury, or exposure at greater than routine levels, requiring more than minor medical intervention, extended surveillance, or leading to serious complications or death Reportable incidents under applicable federal standards (examples provided) Noncompliance or deficiency that substantively compromises research safety oversight programs Research suspensions/terminations related to human welfare Unauthorized lab decommissions or reassignments requiring identification and disposal of hazardous/infectious materials [ § 9]

Office of Research Oversight 22 Reportable Events for Research Laboratory Security Injury or harm to any human being or lab animal related to break-in, security breach, or other security problem Any BSL-3 lab break-in or security breach Any break-in or security breach resulting in any loss of select agent or toxin or highly hazardous agent, substantial damage to the facility, or substantial loss of equipment/resources Noncompliance or deficiency that substantively compromises research laboratory security programs Research suspensions/terminations related to lab security External noncompliance findings [ § 10]

Office of Research Oversight 23 Reportable Events for Research Information Protection Report to ACOS/R, ISO, and Privacy Officer within 1 Hour Unauthorized access, use, disclosure, transmission, removal, theft, or loss related to research of VA Sensitive Information, including PHI, individually identifiable private information, or confidential information per Privacy Act, HIPAA, or Federal Records requirements Any NSOC-reportable incident Report within 5 business days Noncompliance or deficiency that substantively compromises research information protection programs Research suspensions/terminations for info protection concerns External noncompliance findings [ § 11]

Office of Research Oversight 24 Research Misconduct NOTIFY ORO CENTRAL OFFICE AS SOON AS POSSIBLE (BY TELEPHONE OR ) ABOUT ANY ALLEGATIONS OF RESEARCH MISCONDUCT [ § 12]